Renal Anemia - Pipeline Review, H2 2011

Published : October 2011
No. of Pages : 56

Price:

Summary

Global Markets Direct’s, 'Renal Anemia - Pipeline Review, H2 2011', provides an overview of the Renal Anemia therapeutic pipeline. This report provides information on the therapeutic development for Renal Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Anemia. 'Renal Anemia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Renal Anemia.
- A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Renal Anemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Renal Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Renal Anemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Renal Anemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Renal Anemia 8
Renal Anemia Therapeutics under Development by Companies 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Renal Anemia Therapeutics - Products under Development by Companies 15
Companies Involved in Renal Anemia Therapeutics Development 16
Hospira, Inc. 16
Medgenics Inc. 16
FibroGen, Inc. 17
Zydus Cadila Healthcare Limited 17
Lipoxen PLC 18
Affymax, Inc. 18
Acceleron Pharma, Inc. 19
Akebia Therapeutics, Inc. 19
Renal Anemia - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
FG-2216 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
FG-4592 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Peginesatide - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ACE-011 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
EPODURE - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AKB-6548 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ErepoXen - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Erythropoietin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PEG-EPO - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Biosimilar Erythropoietin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Renal Anemia Therapeutics – Drug Profile Updates 39
Renal Anemia Therapeutics - Discontinued Products 45
Renal Anemia - Featured News 46
Oct 10, 2011: Affymax And Takeda To Present Peginesatide Data At American Society of Nephrology Kidney Week 2011 46
Sep 06, 2011: Hospira Announces Positive Results From Phase I US Clinical Trial Of Biosimilar Erythropoietin In Renal Patients 47
Aug 11, 2011: Affymax Announces Assignment Of PDUFA Date For Peginesatide New Drug Application 47
Aug 10, 2011: Affymax Receives $10m Milestone Payment For FDA Filing Of New Drug Application For Peginesatide 48
May 03, 2011: FibroGen Reports Proof-of-Principle For Oral Anemia Therapy FG-4592 In Hemodialysis Patients Switched From Intravenous rhEPO In Phase II Study 48
Mar 17, 2011: FibroGen Initiates Phase IIb Studies Of FG-4592 For Anemia Treatment In Chronic Kidney Disease 51
Dec 16, 2010: Lipoxen Reports Positive Phase II Clinical Data Of ErepoXen 52
Nov 29, 2010: Affymax And Takeda Confirm US Registration Strategy For Hematide Following Meeting with FDA 53
Nov 19, 2010: FibroGen To Present Phase IIa Results Of FG-4592 At American Society Of Nephrology Renal Week 53
Oct 26, 2010: Rockwell Medical Receives Soluble Ferric Pyrophosphate Patent For GMP Formulation In US 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 56
Contact Us 56
Disclaimer 56

Renal Anemia - Pipeline Review, H2 2011

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: